Alopecia is an autoimmune disorder that causes hair loss on the scalp and other areas of the body. According to the National Alopecia Areata Foundation, it accounts for around 2% of the global population, with a rising prevalence driving research into effective therapeutic options. The alopecia pipeline analysis by Expert Market Research highlights the growing focus on novel treatments, including JAK inhibitors, regenerative therapies, and biologics. Increasing awareness, improved diagnosis, and advancements in dermatological research are fueling the growth in the development of alopecia therapeutic products. The market is expected to expand significantly in the coming years, supported by strong clinical trial activity and innovative drug development.
Major companies involved in the alopecia pipeline analysis include Veradermics, Inc., Applied Biology, Inc., and others.
Leading drugs currently in the pipeline include KX-826, PP405, and others.
The pipeline for alopecia is poised for growth, driven by advancements in JAK inhibitors, increased clinical trials targeting androgenetic alopecia, and rising investments in regenerative and stem cell therapies.
The Alopecia Pipeline Analysis Report by Expert Market Research gives comprehensive insights into alopecia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Alopecia. The alopecia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The alopecia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with alopecia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to alopecia.
Alopecia is a medical condition that causes partial or complete hair loss on the scalp or body. It primarily occurs when the immune system mistakenly attacks hair follicles, leading to hair shedding. Alopecia can manifest suddenly and may be triggered by genetic, environmental, or autoimmune factors. The condition affects individuals of all ages and genders.
Alopecia treatment includes corticosteroids, topical immunotherapy, and Janus kinase (JAK) inhibitors, which help manage inflammation and stimulate hair regrowth in affected patients. In June 2023, Pfizer’s ritlecitinib (Litfulo), a JAK inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for treating alopecia areata in adolescents and adults, offering a promising drug pipeline advancement.
According to the National Alopecia Areata Foundation, alopecia areata affects approximately 2% of the global population, impacting around 160 million people worldwide. In the United States, nearly 7 million individuals have experienced or are currently affected, with over 700,000 active cases. Over 80% of cases develop before age 40, and 40% before age 20. Women and individuals from Asian, Black, and Hispanic populations show higher prevalence rates compared to White individuals, according to United States based epidemiological studies.
This section of the report covers the analysis of alopecia drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with nearly 33% covers a major share of the total alopecia clinical trials, reflecting strong innovation and ongoing clinical research. Phase III accounts for approximately 29%, showing promising advancement toward regulatory approval. Phase I contributes 16%. This balanced pipeline supports sustained growth and future treatment breakthroughs in the alopecia treatment market.
The drug molecule categories covered under the alopecia pipeline analysis include small molecules, monoclonal antibodies, cell-based therapies, gene therapies, peptides, and others. The alopecia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for alopecia.
Small interfering RNA (siRNA)-based therapies are gaining attention as a novel drug class in the alopecia treatment pipeline. For example, ALY-101, developed by Alys Pharmaceuticals, targets the JAK1 protein via intradermal delivery to suppress immune responses in alopecia areata. This approach offers localized action with minimized systemic exposure and is currently undergoing evaluation in a Phase IIa clinical trial.
The EMR report for the alopecia pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed alopecia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in alopecia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for alopecia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of alopecia drug candidates.
KX-826, developed by Suzhou Kintor Pharmaceutical Inc., is a topical androgen receptor antagonist currently undergoing a Phase 2/3 trial to evaluate its efficacy and safety in Chinese male patients with androgenetic alopecia. The study is exploring whether KX-826, by blocking DHT-mediated signaling, promotes hair regrowth and prevents follicle miniaturization. The trial is enrolling 756 participants and will be continuing until mid-2028.
PP405 is a novel topical small-molecule gel sponsored by Pelage Pharmaceuticals, Inc., currently undergoing a Phase 2a trial to assess its safety, pharmacokinetics, and efficacy in adults with androgenetic alopecia (AGA). The study aims to validate safety results from a prior Phase 1 trial while examining PP405’s ability to reactivate dormant hair follicle stem cells and stimulate natural hair regrowth through targeted regenerative mechanisms.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Alopecia Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for alopecia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into alopecia collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
